CytRx

CytRx Corp. (NASDAQCYTR) is a biopharmaceutical research and development oncology company in Los Angeles, California.

The CytRx oncology pipeline includes three programs in clinical development: bafetinib, tamibarotene and INNO-206. The company is evaluating bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), a pharmacokinetic clinical trial in brain cancer and the PROACT Phase 2 clinical trial in advanced prostate cancer. With its tumor-targeting pro-drug candidate INNO-206, CytRx is conducting a safety trial with plans to initiate Phase 2 proof-of-concept clinical trials as a treatment for soft tissue sarcomas and pancreatic cancer. CytRx's pipeline also includes tamibarotene, which it is testing in patients with non-small-cell lung cancer and which is in a registration clinical trial as a treatment for acute promyelocytic leukemia (APL).

Arimoclomol (INN, originally codenamed BRX-220) is an experimental drug developed by CytRx. The orally administered drug is intended to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.

See also http://en.wikipedia.org/wiki/Steven_Arthur_Kriegsman

==External links==